CoChat
Sign Up
Cited by 287

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Treating Disease at the RNA Level with Oligonucleotides

Levin, Arthur A.·2019·New England Journal of Medicine
DOI 10.1056/nejmra1705346
Open this paper in CoChat — free account

Abstract

Interview with Dr. Arthur A. Levin on the use of oligonucleotide drugs that regulate RNA. (10:24)Download As research on the structure and function of RNAs has rapidly expanded, so too has the number of oligonucleotide drugs in clinical development that regulate RNA. This article describes several examples and suggests where the field is headed.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmra1705346

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Some ASOs are clinically approved for certain neuromuscular diseases and are currently in trials for other conditions.

    “Some ASOs were clinically approved for certain neuromuscular diseases and are currently in trials for other conditions.184,185”

    From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [185]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 61

  1. 10.1073/pnas.75.1.280 · DOI
  2. 10.1056/NEJMoa1208760 · DOI · Paper page
  3. 10.1056/NEJMoa1702752 · DOI · Paper page
  4. 10.1056/NEJMoa1405760 · DOI
  5. 10.1006/geno.1995.1111 · DOI
  6. 10.1002/wrna.1276 · DOI
  7. 10.1016/j.bbadis.2008.09.017 · DOI
  8. Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989;45:498-506.2491009
  9. 10.1089/nat.2017.0682 · DOI
  10. 10.1006/nbdi.1996.0010 · DOI
  11. 10.1074/jbc.M107632200 · DOI
  12. 10.1016/j.ajhg.2009.08.002 · DOI
  13. 10.1371/journal.pbio.0050073 · DOI
  14. 10.1083/jcb.201207087 · DOI
  15. 10.1016/j.jacc.2009.11.069 · DOI
  16. 10.1161/CIRCULATIONAHA.105.606442 · DOI
  17. 10.1016/S0140-6736(10)60284-X · DOI
  18. 10.1016/j.jacl.2016.04.013 · DOI
  19. 10.1056/NEJMp1614154 · DOI
  20. 10.1056/NEJMoa1716793 · DOI
  21. 10.1093/nar/28.6.1340 · DOI
  22. 10.1002/bit.21798 · DOI
  23. Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18:305-319.19025401
  24. 10.1073/pnas.95.21.12631 · DOI
  25. 10.4049/jimmunol.164.3.1617 · DOI
  26. 10.1089/hum.2007.179 · DOI
  27. 10.1016/j.ymthe.2005.11.002 · DOI
  28. 10.1111/bcp.12961 · DOI · Paper page
  29. 10.1200/JCO.1999.17.11.3586 · DOI
  30. 10.1158/1078-0432.CCR-07-1310 · DOI
  31. Crooke ST Baker BF Pham NC et al. The effects of 2′-O -methoxyethyl oligonucleotides on renal function in humans. Nucleic Acid Ther 2018;28:10-22.29185862 · DOI
  32. 10.1053/j.ajkd.2013.02.359 · DOI
  33. 10.1111/bcp.12738 · DOI
  34. 10.1016/j.omtn.2016.12.003 · DOI
  35. 10.1016/j.jconrel.2016.06.036 · DOI
  36. 10.1038/nature08956 · DOI
  37. 10.1038/ncomms8321 · DOI · Paper page
  38. 10.1038/ncomms1285 · DOI
  39. 10.1016/j.immuni.2014.05.019 · DOI
  40. 10.1038/nbt.1807 · DOI · Paper page
  41. 10.1016/j.jconrel.2016.02.037 · DOI
  42. 10.1016/j.bcp.2017.06.122 · DOI
  43. 10.1038/cr.2016.22 · DOI
  44. Li L-C ed. RNA activation. Singapore: Springer 2017. · DOI
  45. 10.1007/978-981-10-4310-9_11 · DOI
  46. 10.1016/j.ymthe.2017.07.018 · DOI
  47. 10.1038/nrm.2015.4 · DOI · Paper page
  48. 10.1146/annurev-biochem-060208-105251 · DOI · Paper page
  49. 10.1073/pnas.1306243110 · DOI
  50. 10.1146/annurev-biophys-062215-010822 · DOI · Paper page
  51. 10.1126/science.aaq0180 · DOI · Paper page
  52. 10.1038/gt.2016.72 · DOI
  53. 10.1016/j.jconrel.2017.09.012 · DOI · Paper page
  54. Charlesworth CT, Deshpande PS, Dever DP, et al. Identification of pre-existing adaptive immunity to Cas9 proteins in humans. bioRxiv. January 5, 2018.
  55. 10.1038/nbt.2661 · DOI
  56. 10.1158/0008-5472.CAN-10-2978 · DOI
  57. 10.1056/NEJMoa1209026 · DOI
  58. 10.1073/pnas.0805038105 · DOI
  59. 10.1111/ced.12734 · DOI
  60. 10.3892/br.2017.900 · DOI
  61. 10.1002/hep.23922 · DOI

Cited by

Sorted by citations

Metadata

Authors
Levin, A. A.
Affiliations
From Research and Development, Avidity Biosciences, La Jolla, CA.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2019-01-03
Volume
380
Issue
1
Pages
57-70
ISSN
  • 0028-4793
  • 1533-4406
DOI
10.1056/nejmra1705346
Cited by
287
References
15
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review